Responses
Regular and Young Investigator Award Abstracts
Clinical Trial Completed
597 Preliminary results from LuCa-MERIT-1, a first-in-human Phase I trial evaluating the fixed antigen RNA vaccine BNT116 in patients with advanced non-small cell lung cancer
Compose a Response to This Article
Other responses
No responses have been published for this article.
